[18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner

被引:0
作者
Nicolas Graf
Ken Herrmann
Barbara Numberger
Daniela Zwisler
Michaela Aichler
Annette Feuchtinger
Tibor Schuster
Hans-Jürgen Wester
Reingard Senekowitsch-Schmidtke
Christian Peschel
Markus Schwaiger
Ulrich Keller
Tobias Dechow
Andreas K. Buck
机构
[1] Technische Universität München,Department of Hematology/Oncology
[2] Technische Universität München,Department of Nuclear Medicine
[3] Technische Universität München,Institute of Pathology (Helmholtz Zentrum München)
[4] Technische Universität München,Institute of Medical Statistics and Epidemiology
[5] Universitätsklinikum Würzburg,Department of Nuclear Medicine
[6] Schön Klinik Starnberger See,Department of Hematology and Oncology
来源
European Journal of Nuclear Medicine and Molecular Imaging | 2013年 / 40卷
关键词
FLT PET; FDG PET; Lymphoma; Dose-dependency; Therapy monitoring;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:34 / 43
页数:9
相关论文
共 197 条
[21]  
van Waarde A(2002)Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma Ann Oncol 13 1356-1903
[22]  
Cobben DC(2010)Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma J Clin Oncol 28 1896-318
[23]  
Suurmeijer AJ(2009)High incidence of false-positive PET scans in patients with aggressive non-Hodgkin’s lymphoma treated with rituximab-containing regimens Ann Oncol 20 309-1695
[24]  
Maas B(2010)Dose–response relationship in cyclophosphamide-treated B-cell lymphoma xenografts monitored with [18F]FDG PET Eur J Nucl Med Mol Imaging 37 1688-238
[25]  
Vaalburg W(1986)Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution J Nucl Med 27 235-468
[26]  
Shields AF(2011)Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial Lancet Oncol 12 460-674
[27]  
Mankoff DA(2011)Hallmarks of cancer: the next generation Cell 144 646-200
[28]  
Link JM(2002)DNA and its associated processes as targets for cancer therapy Nat Rev Cancer 2 188-177
[29]  
Graham MM(1998)SCID mouse models of human stem cell engraftment Stem Cells 16 166-688
[30]  
Eary JF(2003)[(18)F]FDG-PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging 30 682-1980